WO2023194800 - ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF
National phase entry:
Publication Number
WO/2023/194800
Publication Date
12.10.2023
International Application No.
PCT/IB2023/000193
International Filing Date
05.04.2023
Title **
[English]
ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN TROP2 AND USE THEREOF
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT COMPRENANT UN ANTICORPS CONTRE LE TROP2 HUMAIN ET SON UTILISATION
Applicants **
LIGACHEM BIOSCIENCES INC.
Inventors
PARK, Chang, Sik
SONG, Ho, Young
KIM, Hye, Jung
CHUNG, Chul-Woong
ALBERTI, Saverio
Priority Data
10-2022-0043049
06.04.2022
KR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| * | |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6246 | |
| EPO | Filing, Examination, Granting | 138138 | |
| Japan | Filing, Examination, Granting | 4963 | |
| South Korea | Filing, Examination, Granting | 6358 | |
| USA | Filing, Examination, Granting | 34840 |
Total:
190,545
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to an antibody-drug conjugate (ADC) targeting human TROP2 (tumor-associated calcium signal transducer 2, TACSTD2)) and use thereof, and more particuarly, to: an ADC including an antibody or antigen-binding fragment thereof that binds to human TROP2; and use of ADCs for producing a drug for the treatment and/or treatment of diseases, more particularly, hyperproliferative and/or angiogenic diseases, such as cancer diseases.[French]
La présente invention concerne un conjugué anticorps-médicament (ADC) ciblant le TROP2 humain (transducteur de signal calcique associé à une tumeur 2, (TACSTD2)) et son utilisation, et plus particulièrement : un ADC comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie au TROP2 humain; et l'utilisation d'ADC pour produire un médicament pour le traitement et/ou le traitement de maladies, plus particulièrement, de maladies hyperprolifératives et/ou angiogéniques, telles que des maladies cancéreuses.